PMID- 31177228
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20200916
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 70
IP  - 1
DP  - 2019
TI  - Higher Plasma Level of Nampt Presaging Memory Dysfunction in Chinese Type 2 
      Diabetes Patients with Mild Cognitive Impairment.
PG  - 303-314
LID - 10.3233/JAD-190269 [doi]
AB  - BACKGROUND: In addition to glucose metabolism, adipocytokine Nicotinamide 
      phosphoribosyltransferase (Nampt) has been proposed as a multifunctional protein 
      involved in insulin resistance. Insulin resistance always occurs before the onset 
      of type 2 diabetes mellitus (T2DM) and damages the cognition of T2DM patients 
      very early. OBJECTIVE: We aimed to investigate the role and potential clinical 
      value of Nampt in early cognitive decline of T2DM. METHODS: A total of 195 
      Chinese T2DM patients were enrolled and divided into a mild cognition impairment 
      (MCI) group and a healthy cognition group according to Montreal Cognitive 
      Assessment (MoCA) score. Their cognitive function was extensively assessed. The 
      plasma level of Nampt was measured via enzyme-linked immunosorbent assay. 
      RESULTS: In the MCI group (n = 78, MoCA < 26), the plasma level of Nampt was 
      significantly higher than the controls (p < 0.01). After adjusting for age, sex, 
      and level of education, Nampt levels were negatively associated with most of the 
      cognitive domains forecasting hypomnesia (all p < 0.007). Nevertheless, 
      hierarchical regression analysis further revealed that Nampt was an independent 
      risk factor of MCI in Chinese T2DM patients (all p < 0.05), including Logic 
      Memory Test (beta= -0.31, p < 0.01), Auditory Verbal Learning Test delayed recall 
      (beta= -0.26, p < 0.01), and so on, which represent memory function. Correlation 
      analysis showed that Nampt related to insulin resistance (HOMA-IR), glycosylated 
      hemoglobin (HbA1c), and lipid levels (all p < 0.05). CONCLUSIONS: We found that 
      higher plasma level of Nampt presages memory dysfunction in MCI in Chinese T2DM 
      patients. Further studies are necessary to confirm its scanning and prognosis 
      prediction value of the disease clinically.
FAU - Huang, Xi
AU  - Huang X
AD  - Department of Endocrinology, The Affiliated ZhongDa Hospital of Southeast 
      University, Nanjing, PR China.
FAU - Wang, Chenchen
AU  - Wang C
AD  - Department of Endocrinology, The Affiliated ZhongDa Hospital of Southeast 
      University, Nanjing, PR China.
AD  - Medical School of Southeast University, Nanjing, PR China.
FAU - Tian, Sai
AU  - Tian S
AD  - Medical School of Southeast University, Nanjing, PR China.
FAU - Huang, Rong
AU  - Huang R
AD  - Medical School of Southeast University, Nanjing, PR China.
FAU - Guo, Dan
AU  - Guo D
AD  - Medical School of Southeast University, Nanjing, PR China.
FAU - Zhang, Haoqiang
AU  - Zhang H
AD  - Medical School of Southeast University, Nanjing, PR China.
FAU - Shi, Jijing
AU  - Shi J
AD  - Medical School of Southeast University, Nanjing, PR China.
FAU - Wang, Shaohua
AU  - Wang S
AD  - Department of Endocrinology, The Affiliated ZhongDa Hospital of Southeast 
      University, Nanjing, PR China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
RN  - 0 (Biomarkers)
RN  - EC 2.4.2.12 (Nicotinamide Phosphoribosyltransferase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - China
MH  - Cognitive Dysfunction/*blood/complications
MH  - Diabetes Mellitus, Type 2/*blood/complications
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Male
MH  - Memory Disorders/*blood/complications
MH  - Middle Aged
MH  - Neuropsychological Tests
MH  - Nicotinamide Phosphoribosyltransferase/*blood
OTO - NOTNLM
OT  - Adipocytokine
OT  - Alzheimer's disease
OT  - hypomnesia
OT  - mild cognition impairment
OT  - nicotinamide phosphoribosyltransferase
OT  - type 2 diabetes
EDAT- 2019/06/10 06:00
MHDA- 2020/09/17 06:00
CRDT- 2019/06/10 06:00
PHST- 2019/06/10 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2019/06/10 06:00 [entrez]
AID - JAD190269 [pii]
AID - 10.3233/JAD-190269 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2019;70(1):303-314. doi: 10.3233/JAD-190269.